OS Therapies (OSTX) News Today $1.56 +0.01 (+0.97%) As of 03:51 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period OS Therapies granted FDA meeting for OST-HER2April 22 at 9:37 PM | markets.businessinsider.comOS Therapies FDA Meeting Request GrantedApril 22 at 7:40 AM | businesswire.comOS Therapies Inc (NYSE:OSTX) Major Shareholder Sells $67,516.20 in StockApril 12, 2025 | insidertrades.comOS Therapies Announces Positive Data From The Study Of OST-HER2 In Osteosarcoma In DogsApril 12, 2025 | nasdaq.comOS Therapies Inc: Shalom Auerbach sells $81,566 in common stockApril 11, 2025 | investing.comOS Therapies Announces Positive Data for OST-HER2 in the Treatment of Unresected Osteosarcoma in Dogs Opening the Potential for Use as Front-Line Therapy in HumansApril 10, 2025 | businesswire.comOS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala PharmaceuticalsApril 9, 2025 | businesswire.comLake Street Initiates Coverage of OS Therapies (OSTX) with Buy RecommendationApril 3, 2025 | msn.comOS Therapies Inc Reports 2024 Net Loss Per Share of $0. ...April 1, 2025 | gurufocus.comOS Therapies Reports Full Year 2024 Financial Results and Provides Business UpdateMarch 31, 2025 | businesswire.comOS Therapies Provides Regulatory Update on Rare Pediatric Cancer Immunotherapy Candidate OST-HER2 for Human OsteosarcomaMarch 31, 2025 | businesswire.comOS Therapies’ OST-HER2 Immunotherapy for Osteosarcoma Featured in Upcoming Movie Shelter Me: The Cancer PioneersMarch 25, 2025 | finance.yahoo.comOS Therapies' OST-HER2 Immunotherapy for Osteosarcoma Featured in Upcoming Movie Shelter Me: The Cancer PioneersMarch 25, 2025 | businesswire.comOS Therapies (OSTX): Among the Penny Stocks With Huge Upside Potential According to AnalystsMarch 23, 2025 | insidermonkey.comOS Therapies to Attend The Jones Healthcare and Technology Innovation ConferenceMarch 21, 2025 | businesswire.comOS Therapies Awarded OST-HER2 Clinical Trial Data Presentation at MIB Agents FACTOR Osteosarcoma ConferenceMarch 13, 2025 | businesswire.comOS Therapies schedules Scientific Advice Meeting for OST-HER2 in Q3March 11, 2025 | markets.businessinsider.comSpin-Offs as Catalysts: Unlocking Value, Driving Growth, and Creating Opportunities for Big GainsMarch 4, 2025 | theglobeandmail.comJoin OS Therapies’ Exclusive Live Investor Webinar and Q&A Session on February 27February 26, 2025 | finance.yahoo.comJoin OS Therapies' Exclusive Live Investor Webinar and Q&A Session on February 27February 26, 2025 | businesswire.comOS Therapies receives patent notice of allowance for OST-HER2February 20, 2025 | markets.businessinsider.comOS Therapies Receives Patent Notice of Allowance from U.S. Patent & Trademark Office Covering Commercial Manufacturing of OST-HER2February 20, 2025 | businesswire.comOS Therapies Inc (NYSE:OSTX) Major Shareholder Sells $284,000.00 in StockFebruary 19, 2025 | insidertrades.comOSTX Stock Earnings: OS Therapies Reported Results for Q2 2024February 14, 2025 | investorplace.comOS Therapies gears up for FDA meeting on cancer drugFebruary 14, 2025 | msn.comOS Therapies initiates commercial manufacturing of OST-HER2February 14, 2025 | markets.businessinsider.comSmall-Cap OS Therapies Inks Commercial Manufacture Agreements For Lead Cancer Drug For Rare Type Of Bone CancerFebruary 14, 2025 | benzinga.comOS Therapies Initiates Commercial-ready Manufacturing of OST-HER2 to Support Anticipated Biologics Licensing Authorization (BLA) FilingFebruary 14, 2025 | businesswire.comOS Therapies gears up for osteosarcoma drug approvalFebruary 4, 2025 | msn.comOS Therapies Provides Corporate UpdateFebruary 4, 2025 | businesswire.comOS Therapies files to sell 10.83M shares of common stock for holdersFebruary 1, 2025 | markets.businessinsider.comOS Therapies Inc trading resumesJanuary 30, 2025 | markets.businessinsider.comOS Therapies (NYSE:OSTX) Earns "Buy" Rating from D. Boral CapitalD. Boral Capital reaffirmed a "buy" rating and set a $20.00 price objective on shares of OS Therapies in a research report on Thursday.January 30, 2025 | marketbeat.comOS Therapies Inc's Lock-Up Period Will Expire on January 28th (NYSE:OSTX)OS Therapies' (NYSE:OSTX - Get Free Report) lock-up period is set to end on Tuesday, January 28th. OS Therapies had issued 1,600,000 shares in its IPO on August 1st. The total size of the offering was $6,400,000 based on an initial share price of $4.00. After the expiration of the company's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.January 21, 2025 | marketbeat.comOS Therapies Inc (NYSE:OSTX) Major Shareholder Sells $112,692.80 in StockJanuary 18, 2025 | insidertrades.comos therapies sees $112,609 in stock sales by Einodmil LLCJanuary 17, 2025 | msn.comShalom Auerbach Sells 16,720 Shares of OS Therapies Inc (NYSE:OSTX) StockOS Therapies Inc (NYSE:OSTX - Get Free Report) major shareholder Shalom Auerbach sold 16,720 shares of the business's stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $6.74, for a total value of $112,692.80. Following the completion of the transaction, the insider now owns 2,531,211 shares of the company's stock, valued at $17,060,362.14. This represents a 0.66 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link. Large shareholders that own at least 10% of a company's shares are required to disclose their transactions with the SEC.January 17, 2025 | marketbeat.comOS Therapies price target raised to $15 from $8 at MaximJanuary 17, 2025 | finance.yahoo.comOS Therapies’s HER2 therapy prevents lung cancer recurrence in 33% patientsJanuary 16, 2025 | msn.comOS Therapies: A Cheap Mid-Stage Biotech Carrying Listeria-Based ImmunotherapyJanuary 16, 2025 | seekingalpha.comOS Therapies (NYSE:OSTX) Price Target Raised to $15.00 at Maxim GroupMaxim Group lifted their price objective on shares of OS Therapies from $8.00 to $15.00 and gave the company a "buy" rating in a report on Thursday.January 16, 2025 | marketbeat.comOS Therapies' (OSTX) Buy Rating Reiterated at D. Boral CapitalD. Boral Capital restated a "buy" rating and set a $20.00 price target on shares of OS Therapies in a research note on Wednesday.January 16, 2025 | marketbeat.comOS Therapies up 65% as lung osteosarcoma asset meets goal in phase 2 trialJanuary 15, 2025 | msn.comD. Boral Capital Reiterates "Buy" Rating for OS Therapies (NYSE:OSTX)D. Boral Capital reaffirmed a "buy" rating and issued a $20.00 price target on shares of OS Therapies in a report on Wednesday.January 15, 2025 | marketbeat.comOS Therapies stock soars on Phase 2b trial successJanuary 15, 2025 | in.investing.comOS Therapies Announces Phase 2b Clinical Trial of OST-HER2 Achieves Primary Endpoint with Statistical Significance in the Prevention of Recurrent, Fully Resected, Lung Metastatic OsteosarcomaJanuary 15, 2025 | businesswire.comRockville's OS Therapies raises millions to get cancer treatment to marketJanuary 8, 2025 | bizjournals.comOS Therapies to Attend the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 2, 2025 | finance.yahoo.comOS Therapies Announces Closing of $6 Million Private PlacementDecember 31, 2024 | businesswire.comOS Therapies Partners with B2i Digital to Engage with Biotech Investors OnlineDecember 26, 2024 | businesswire.com Get OS Therapies News Delivered to You Automatically Sign up to receive the latest news and ratings for OSTX and its competitors with MarketBeat's FREE daily newsletter. Email Address OSTX Media Mentions By Week OSTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OSTX News Sentiment▼0.170.72▲Average Medical News Sentiment OSTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OSTX Articles This Week▼32▲OSTX Articles Average Week Get OS Therapies News Delivered to You Automatically Sign up to receive the latest news and ratings for OSTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Coherus BioSciences News Today FitLife Brands News Today Eupraxia Pharmaceuticals News Today Editas Medicine News Today Instil Bio News Today Neumora Therapeutics News Today Procaps Group News Today Fate Therapeutics News Today Enanta Pharmaceuticals News Today Tonix Pharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:OSTX) was last updated on 4/24/2025 by MarketBeat.com Staff From Our PartnersDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredFeds Just Admitted It—They Can Take Your CashHere’s the cold truth: If your money is sitting idle in a bank account, it’s vulnerable. That’s why thousan...Priority Gold | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe Exact July Date the AI Correction Will End?AI stocks have cooled off—but Jeff Brown, the tech expert who picked Nvidia before it soared 222x, says one da...Brownstone Research | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredVirtually Limitless Energy?A radical energy breakthrough could change everything. Scientists at MIT and a stealth startup may have discov...Stansberry Research | SponsoredMusk’s real agenda in D.C. In this urgent exposé, you’ll discover… How Elon and Donald Trump are quietly drawing a radical new map of ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OS Therapies Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share OS Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy OSTX Stock Free OSTX Stock Alerts